skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

Original Research

(1541) Views  (391) Full article downloads

Authors: Xiaomei Peng, Haya Ascher-Svanum, Douglas Faries et al

Published Date January 2011 Volume 2011:3 Pages 9 - 14
DOI: http://dx.doi.org/10.2147/CEOR.S16061

Xiaomei Peng, Haya Ascher-Svanum, Douglas Faries, Robert R Conley, Kory J Schuh
Eli Lilly and Company, Indianapolis, IN, USA

Purpose: To assess change in hospitalization and cost of care from 6 months pre- to 6 months post-initiation on any depot antipsychotic among schizophrenia patients.
Patients and methods: Using a large United States commercial claims and encounters database, patients younger than 65 years diagnosed with schizophrenia were identified. Patients initiated on a depot antipsychotic were studied in a mirror-image design to assess change in hospitalization rates, mean duration hospitalized, and hospitalization cost. McNemar’s test and paired t-tests compared the proportions of patients hospitalized and the mean duration. Paired t-test and bootstrapping methods compared costs.
Results: In these patients (n = 147), psychiatric hospitalizations declined from 49.7% pre-initiation to 22.4% post-initiation (P < 0.001), and the mean hospitalized duration for psychiatric purposes numerically declined from 7.3 to 4.7 days (P = 0.05). Total health care costs declined from $11,111 to $7884 (P < 0.05) driven by reduction in costs for psychiatric hospitalizations from $5384 to $2538 (P < 0.05).
Conclusion: Initiation of depot antipsychotic therapy appeared to be associated with a decline in hospitalization rates and costs. Current findings suggest that treatment with depot antipsychotics may be a cost-effective option for a subgroup of patients with schizophrenia who are at high risk of nonadherence with their oral antipsychotic medication regimen.

Keywords: mirror-image, claims database, treatment outcomes, depot antipsychotics




 

Other articles by Dr Haya Ascher-Svanum



Readers of this article also read:

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum